Navigation Links
George W. Sledge, Jr., M.D., honored for international contributions to breast cancer research
Date:12/6/2010

SAN ANTONIO George W. Sledge Jr., M.D., a nationally recognized pioneer in the development of novel therapies for breast cancer, will receive the 2010 William L. McGuire Memorial Lecture Award at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.

Supported by GlaxoSmithKline Oncology (GSK) since its inception in 1992, this honor acknowledges distinguished internationally recognized researchers for their significant contributions to breast cancer research.

Sledge is the Ballve-Lantero Professor of Oncology and professor of medicine and pathology at the Indiana University School of Medicine, and a physician/ researcher at the Indiana University Melvin and Bren Simon Cancer Center. He is also co-director of the the IU Simon Cancer Center's breast program. Sledge specializes in the study and treatment of breast cancer, and his research specifically focuses on molecular and tumor biology, growth factors and anti-angiogenic therapy. He has chaired several nationwide clinical trials involving new therapies for breast cancer.

"Dr. Sledge's work developing novel therapies to treat women with breast cancer has improved the lives of countless cancer patients," said C. Kent Osborne, M.D., codirector of the San Antonio Breast Cancer Symposium and director of the Baylor College of Medicine Dan L. Duncan Cancer Center. "The selection of Dr. Sledge is even more appropriate since he was one of the first medical oncology fellows to graduate the new fellowship training program at the University of Texas Health Science Center Division of Medical Oncology, established by Dr. McGuire as division director in the late 1970s. We congratulate Dr. Sledge on this fitting honor."

Sledge will give a lecture entitled, "What Would Bill Do? Channeling Your Inner McGuire," on Saturday, Dec. 11, 2010, at 11:15 a.m. CT, during the 33rd Annual San Antonio Breast Cancer Symposium. This symposium, encompassing the full spectrum of breast cancer research, will be held Dec. 8-12, 2010, at the Henry B. Gonzalez Convention Center, San Antonio, Texas.

Paolo Paoletti, M.D., senior vice president and head of the oncology R&D unit at GlaxoSmithKline, said "Dr. Sledge has been a true visionary and pioneer in the progression of pathway-related treatments for breast cancer and other diseases. His work with HER2-positive, anti-angiogenesis treatment helped herald a new era in the treatment of breast cancer, and millions of patients have benefitted from this advancement in science. Admirably, all of Dr. Sledge's contributions to research were done with a unique attention and commitment for patients' feelings and needs, which drive everything he does. This award is befitting of such a tremendous scientist and supporter of patient care."

Sledge joined the Indiana University School of Medicine faculty in 1983, after completing his residency at St. Louis University and his fellowship at the University of Texas, San Antonio. He received his undergraduate degree from the University of Wisconsin and his medical degree from Tulane University.

He holds many honors including the Jill Rose Award Breast Cancer Research Foundation (2007) and the 2006 Komen Foundation Brinker Award for Scientific Distinction. Sledge has been listed among "America's Top Doctors" as well as "America's Top Doctors for Cancer."

Sledge is the current president of ASCO and has been an active member of the AACR since 1988. He has served as a breast cancer committee leader with the Hoosier Oncology Group. He serves as chair of the Eastern Cooperative Oncology Group and in various capacities for The Breast Cancer Intergroup. He was secretary (1997-1998) and a board of trustees member (1995-1998) of the Indiana Medical Oncology Society. Sledge has published extensively in the area of breast cancer research, and has served as editor-in-chief of Clinical Breast Cancer.


'/>"/>

Contact: Michele Sharp
michele.sharp@aacr.org
267-646-0622
American Association for Cancer Research
Source:Eurekalert

Related biology news :

1. Georgetown Universitys Howard J. Federoff, M.D., Ph.D. receives Bernard Sanberg Memorial Award
2. George M. Whitesides receives inaugural Dreyfus prize in the chemical sciences
3. American Society for Microbiology honors George Liu
4. Annual survey shows high numbers of seed scallops on Georges Bank, low numbers in Mid-Atlantic
5. George Whitesides accepts inaugural Dreyfus Prize in the Chemical Sciences
6. George Daley to discuss challenges and opportunities facing stem cell scientists
7. Dr. George Stark receives 2011 Herbert Tabor/Journal of Biological Chemistry Lectureship from ASBMB
8. Little is understood about alcohols effect on fetal development, Georgetown researchers say
9. Chip Supply Hosts Visit by U.S. Senator George LeMieux
10. George Pólya Prize awarded to Emmanuel Candès and Terence Tao
11. Rensselaer Polytechnic Institute professor Georges Belfort wins biochemical engineering award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , ... June 23, 2016 , ... In a new ... in Denmark detail how a patient who developed lymphedema after being treated for breast ... results could change the paradigm for dealing with this debilitating, frequent side effect of ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
Breaking Biology Technology: